Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have been given an average recommendation of “Moderate Buy” by the eight brokerages that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $20.2857.

A number of analysts have recently issued reports on ENTA shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Monday, April 20th. Wall Street Zen lowered Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday, May 31st. Finally, Rodman & Renshaw started coverage on Enanta Pharmaceuticals in a research report on Thursday, March 26th. They set a “buy” rating and a $20.00 target price on the stock.

Enanta Pharmaceuticals Stock Performance

Shares of NASDAQ ENTA opened at $12.07 on Wednesday. Enanta Pharmaceuticals has a 1 year low of $6.43 and a 1 year high of $17.15. The firm has a market cap of $351.00 million, a price-to-earnings ratio of -4.66 and a beta of 0.97. The stock’s 50-day simple moving average is $13.39 and its 200-day simple moving average is $13.69.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its earnings results on Monday, May 11th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.01. Enanta Pharmaceuticals had a negative return on equity of 64.04% and a negative net margin of 89.56%.The business had revenue of $17.16 million for the quarter, compared to analyst estimates of $17.03 million. As a group, research analysts predict that Enanta Pharmaceuticals will post -1.79 EPS for the current year.

Hedge Funds Weigh In On Enanta Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. Deutsche Bank AG grew its stake in Enanta Pharmaceuticals by 4.6% in the fourth quarter. Deutsche Bank AG now owns 24,107 shares of the biotechnology company’s stock worth $380,000 after purchasing an additional 1,055 shares in the last quarter. Public Employees Retirement System of Ohio grew its stake in Enanta Pharmaceuticals by 8.3% in the third quarter. Public Employees Retirement System of Ohio now owns 14,412 shares of the biotechnology company’s stock worth $173,000 after purchasing an additional 1,100 shares in the last quarter. Ameriprise Financial Inc. grew its stake in Enanta Pharmaceuticals by 8.3% in the third quarter. Ameriprise Financial Inc. now owns 18,007 shares of the biotechnology company’s stock worth $216,000 after purchasing an additional 1,383 shares in the last quarter. Quantinno Capital Management LP grew its stake in Enanta Pharmaceuticals by 4.9% in the first quarter. Quantinno Capital Management LP now owns 35,122 shares of the biotechnology company’s stock worth $444,000 after purchasing an additional 1,627 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its stake in Enanta Pharmaceuticals by 13.4% in the third quarter. Russell Investments Group Ltd. now owns 16,443 shares of the biotechnology company’s stock worth $197,000 after purchasing an additional 1,940 shares in the last quarter. 94.99% of the stock is currently owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct?acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.